A cost-effectiveness analysis of first-line controller therapies for persistent asthma

PharmacoEconomics

Volumn 25, Issue 7, 2007, Pages 577-590

  Shih, Ya Chen Tina ^a   Mauskopf, Josephine ^b   Borker, Rohit ^c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; LEUKOTRIENE MODIFIER; SALBUTAMOL; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECISION TREE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; MEDICAL EXPERT; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS;

ANTI-ASTHMATIC AGENTS; ASTHMA; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MODELS, ECONOMIC; RANDOMIZED CONTROLLED TRIALS;

EID: 34447252565     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200725070-00004     Document Type: Article

References (47)

1. National Center for Health Statistics, Centers for Disease Control and Prevention. Asthma prevalence, health care use and mortality, 2000-2001. Hyattsville (MD): Centers for Disease Control and Prevention, 2002
2. Fuhlbrigge AL, Adams RJ, Guilbert TW, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the National Asthma Education and Prevention Program guidelines. Am J Respir Crit Care Med 2002; 166 (8): 1044-9
3. National Heart Lung and Blood Institute. Highlights of the expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institute of Health, 1997
4. Birnbaum HG, Berger WE, Greenberg PE, et al. Direct and indirect costs of asthma to an employer. J Allergy Clin Immunol 2002; 109 (2): 264-70
5. Weiss KB, Sullivan SD. The health economics of asthma and rhinitis: I. Assessing the economic impact. J Allergy Clin Immunol 2001; 107 (1): 3-8
6. Godard P, Chanez P, Siraudin L, et al. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur Resp J 2002; 19 (1): 61-7
7. NAEPP expert panel report: guidelines for the diagnosis and management of asthma. Updates on selected topics 2002. Bethesda (MD): NIH NHLBI, 2002
8. Nelson HS, Chapman KR, Pyke SD, et al. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003; 112 (1): 29-36
9. Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113 (2): 245-51
10. Stempel DA, Roberts CS, Stanford RH. Treatment patterns in the months prior to and after asthma-related emergency department visit. Chest 2004; 126 (1): 75-80
11. Hoskins G, McCowan C, Neville RG, et al. Risk factors and costs associated with an asthma attack. Thorax 2000; 55 (1): 19-24
12. Castro M, Zimmermann NA, Crocker S, et al. Asthma intervention program prevents readmissions in high healthcare users. Am J Respir Crit Care Med 2003; 168 (9): 1095-9
13. Piecoro LT, Potoski M, Talbert JC, et al. Asthma prevalence, cost, and adherence with expert guidelines on the utilization of health care services and costs in a state Medicaid population. Health Serv Res 2001; 36 (2): 357-71
14. Johansson G, Sondhi PM. Cost effectiveness analysis of almeterol/fluticasone propionate 50/100ug vs. flucticasone propionate 100ug in adults and adolescents with asthma III: results. Pharmacoeconomics 1999; 16 Suppl. 2: 15-21
15. Price MJ, Briggs AH. Development of an economic model to assess the cost effectiveness of asthma management strategies. Pharmacoeconomics 2002; 20 (3): 183-94
16. Sheth K, Borker R, Emmett A, et al. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmacoeconomics 2002; 20 (13): 909-18
17. O'Connor RD, Nelson H, Borker R, et al. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22 (12): 815-25
18. Stempel DA, Mauskopf J, McLaughlin T, et al. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95 (3): 227-34
19. Stempel DA, Meyer JW, Stanford RH, et al. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol 2001; 107 (1): 94-8
20. Bukstein DA, Henk HJ, Luskin AT. A comparison of asthma related expenditures for patients started on montelukast versus fluticasone propionate as monotherapy. Clin Ther 2001; 23 (9): 1589-600
21. Pathak DS, Davis EA, Stanford RH. Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population. Pharmacotherapy 2002; 22 (2): 166-74
22. Calhoun WJ, Nelson HS, Nathan RA, et al. Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone. Am J Respir Crit Care Med 2001; 164 (5): 759-63
23. Pearlman DS, White MV, Lieberman AK, et al. Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent asthma. Ann Allergy Asthma Immunol 2002; 88 (2): 227-35
24. Baraniuk J, Murray JJ, Nathan RA, et al. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 1999; 116 (3): 625-32
25. Kavuru M, Melamed J, Gross G, et al. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1108-16
26. Matz J, Emmett A, Rickard K, et al. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107 (5): 783-9
27. Busse W, Wolfe J, Storms W, et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract 2001; 50 (7): 595-602
28. Busse W, Raphael GD, Galant S, et al. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: a randomized clinical trial. J Allergy Clin Immunol 2001; 107 (3): 461-8
29. Kim KT, Ginchansky EJ, Friedman BF, et al. Fluticasone propionate versus zafirlukast: effect in patients previously receiving inhaled corticosteroid therapy. Ann Allergy Asthma Immunol 2000; 85 (5): 398-406
30. Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105 (6 Pt 1): 1123-9
31. Stempel DA, O'Donnell JC, Meyer JW. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 2002; 109 (3): 433-9
32. Zetterstrom O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18 (2): 262-8
33. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130 (6): 487-95
34. Fish JE, Israel E, Murray JJ, et al. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 2001; 120 (2): 423-30
35. Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158 (11): 1213-20
36. Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126 (3): 177-83
37. HealthCare Consultants of America. 2005 Physicians fee and coding guide: a comprehensive fee and coding reference. Atlanta (GA): MAG Mutual HealthCare Solutions, Inc., 2004
38. Drug topics red book. 109th ed. Montvale (NJ): Thomson Medical Economics, 2005
39. Stempel DA, Stanford RH, Thwaites R, et al. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin Ther 2000; 22 (12): 1562-74
40. Bureau of Labor Statistics. Consumer price index: urban wage earners and clerical workers [online]. Available from URL: http://data.bls.gov/cgi-bin/ surveymost?cu [Accessed 2007 Jun 17]
41. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. New York (NY): Oxford University Press, 1997
42. Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patient preferences into health outcomes assessment: the multiattribute asthma symptom utility index. Chest 1998; 114: 998-1007
43. Doubilet P, Begg CB, Weinstein MC, et al. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5 (2): 157-77
44. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 479-500
45. Briggs AH, Ades AE, Price MJ. Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. Med Decis Making 2003; 23 (4): 341-50
46. Stempel DA, Kelly HW. Approaching value in asthma management: the need to integrate clinical and economic research with the basic science. J Allergy Clin Immunol 2002; 109 (5 Suppl.): S503-10
47. Gold MR Seigel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996